Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
- PMID: 34710128
- PMCID: PMC8553049
- DOI: 10.1371/journal.pone.0258949
Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
Abstract
Aims: Impaired renal function is a major contributor to the low proportion of mineralocorticoid receptor antagonist (MRA) treatment in patients with heart failure with reduced ejection fraction (HFrEF). Our aims were to investigate the impact of MRA treatment on all-cause mortality and worsening renal function (WRF) in patients with HFrEF and moderately impaired renal function.
Methods: Retrospective data between 2010-2018 on HFrEF patients from a single-centre hospital with estimated glomerular renal function (eGFR) < 60 ml/min/1.73 m2 were analysed. WRF was defined as a decline of by eGFR ≥ 20%.
Results: 416 patients were included, 131 patients on MRA and 285 without MRA, mean age was 77 years (SD ± 9) and 82 years (SD ± 9), respectively. Median follow-up was 2 years. 128 patients (32%) experienced WRF, 25% in the MRA group and 30% in patients without MRA (p = 0.293). In multivariable analysis, hospitalization for heart failure and systolic blood pressure were associated with WRF (p = 0.015 and p = <0.001), but not use of MRA (p = 0.421). MRA treatment had no impact on the risk of adjusted all-cause mortality (HR 0.93; 95% CI, 0.66-1.32 p = 0.685). WRF was associated with increased adjusted risk of all-cause mortality (HR 1.43; 95% CI, 1.07-1.89 p = 0.014). Use of MRA did not increase the adjusted overall risk of mortality even when experiencing WRF (HR 1.15; 95% CI, 0.81-1.63 p = 0.422).
Conclusion: In this cohort of elderly HFrEF patients with moderately impaired renal function, MRA did not increase risk for WRF or all-cause mortality.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93. doi: 10.1016/j.jacc.2013.04.086. Epub 2013 Jun 27. J Am Coll Cardiol. 2013. PMID: 23810881 Clinical Trial.
-
Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction.Clin Res Cardiol. 2021 Jul;110(7):1051-1062. doi: 10.1007/s00392-020-01790-y. Epub 2021 Jan 4. Clin Res Cardiol. 2021. PMID: 33394127
-
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).Circ Heart Fail. 2014 Jan;7(1):51-8. doi: 10.1161/CIRCHEARTFAILURE.113.000792. Epub 2013 Dec 2. Circ Heart Fail. 2014. PMID: 24297687 Clinical Trial.
-
Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.Circ Heart Fail. 2017 Feb;10(2):e003588. doi: 10.1161/CIRCHEARTFAILURE.116.003588. Circ Heart Fail. 2017. PMID: 28209765 Review.
-
Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction.Eur J Heart Fail. 2014 Jan;16(1):41-8. doi: 10.1002/ejhf.13. Epub 2013 Dec 11. Eur J Heart Fail. 2014. PMID: 24453097 Review.
Cited by
-
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease.Rev Cardiovasc Med. 2024 Apr 11;25(4):144. doi: 10.31083/j.rcm2504144. eCollection 2024 Apr. Rev Cardiovasc Med. 2024. PMID: 39076544 Free PMC article. Review.
References
-
- Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, et al.. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20(9):1326–34. doi: 10.1002/ejhf.1182 - DOI - PubMed
-
- Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). European journal of heart failure. 2009;11(9):847–54. doi: 10.1093/eurjhf/hfp108 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
